Press "Enter" to skip to content

Novavax’s respiratory infection vaccine fails in late-stage trial

(Reuters) – Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

The vaccine failed to prevent lower respiratory tract infection related to RSV, or respiratory syncytial virus, the company said.

Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar

Our Standards:The Thomson Reuters Trust Principles.